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The entire world has been experiencing the outbreak of a novel infectious agent 
known as severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), which is 
responsible for the coronavirus disease 19 (COVID-19)1. Life-threatening 
complications described in SARS-CoV-2 infected patients include acute respiratory 
distress syndrome, acute kidney failure and cardiac injury2. Nonetheless, only few 
neurological complications have been described so far3. 
A recent retrospective study performed in the city of Wuhan, China, reported that 
78/214 (36.4%) patients with COVID-19 presented with nervous system clinical 
findings; mainly dizziness, headache, encephalopathy, stroke, smell and taste 
disorders and musculoskeletal injury4. Zhao and collaborators published the first 
case of a 61-year-old patient presenting with a rapidly evolving ascending weakness 
and mild distal sensory complaints, followed by COVID-19 related symptoms, 
leading to the diagnosis of Guillain-Barré syndrome (GBS)5. Authors concluded that 
SARS-CoV-2 might have triggered GBS in this case, following a para-infectious 
pattern, as described with Zika virus (ZIKV) infection6. A recent series of five GBS 
cases from northern Italy describes a severe disease course with predominant 
axonal involvement7.  
We report a series of three cases of typical GBS preceded by classic signs and 
symptoms of biologically confirmed COVID-19, who were studied in Geneva and 
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12th, 26’144 COVID-19 cases were confirmed in Switzerland and 9360 in our 
catchment area. 
Materials and Methods 
Clinical and ancillary tests description were personally retrieved by the authors, who 
examined the patients. This report is conducted in compliance to Swiss Federal Act 
on Research involving Human Beings that wave ethic approval for case report of 
less than five patients.  
Case reports 
All patients presented with distal paresthesias and rapidly progressive limb 
weakness, evolving to either moderate tetraparesis (2/3) or tetraplegia (1/3) and 
areflexia (3/3) within the first five days. One patient required mechanical ventilation 
due to respiratory failure and two underwent functional hemodynamic monitoring of 
dysautonomic signs. Additionally, two patients presented with pain and only one with 
bulbar signs and facial biplegia. Neurological symptoms appeared within the first 22 
days (7, 15 and 22 days) after the appearance of typical COVID-19 related 
symptoms. For clinical details see supplementary material. 
Laboratory findings showed grade 1 and 2 lymphopenia in 2/3 patients. Anti-
gangliosides antibodies were negative. Cerebrospinal fluid (CSF) analysis showed 
classic albuminocytologic dissociation in 2/3 patients, with a white cell count < 4 
cell/µL (additional results are detailed in Table 1). Reverse-transcription polymerase-
chain-reaction (RT-PCR) assay for SARS-CoV-2 of the CSF was tested in 2/3 
patients with a negative result. Initial RT-PCR extracted from the nasopharyngeal 
swab was positive in two cases. The third case showed a SARS-CoV-2 
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Magnetic resonance imaging was performed in two patients and one disclosed 
gadolinium enhancement of the lumbosacral roots. Nerve conduction studies (NCS) 
revealed a typical demyelinating pattern (3/3) and one case showed nerve 
conduction blocks (supplementary table), which persisted in an exam conducted one 
week later. Needle electromyography was recorded in one patient showing no 
abnormal spontaneous activity.  
All patients were treated with intravenous immunoglobulins (0.4 g/kg/day for five 
days). Clinical outcome was favourable in one patient who was dismissed and able 
to walk without assistance (supplementary material, case 2), another patient was 
able to walk 100-200 metres with aid (case 3). The third patient remained bedbound 
but was able to rise from a chair with assistance (case 1). 
Discussion 
NCS showed a classic demyelinating pattern (AIDP) in the three patients. This 
observation contrasts with previous publications which reported axonal loss 
correlating with a more severe disease course and greater disability at one month7. 
In our cohort, full recovery was observed in one patient, another one was able to 
walk with assistance and the last remained bedridden but was able to rise to 
standing up (GBS disability score at five weeks follow-up of 1/6, 3/6 and 4/6 
respectively).  
The median period between the onset of COVID-19 related-symptoms and 
neurological complaints was fifteen days (7-22 days); longer than the interval 
reported by Toscano and collaborators (5-10 days)7. In addition, PCR SARS-CoV-2 










This article is protected by copyright. All rights reserved 
These observations support the hypothesis that SARS-CoV-2 triggers GBS via a 
secondary immune-mediated mechanism rather than a direct viral neuropathic 
damage, as described after ZIKV infection6. Additional clinical data is needed to 
further elucidate the exact mechanism underlying SARS-CoV-2-associated GBS. 
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Table 1. Clinical characteristics and laboratory findings of three patients with Guillain-Barré syndrome after COVID-19 
 
 Case 1 Case 2 Case 3 
Age/Gender 52/Female 63/Female 61/Female 
Comorbidities None Type 2 diabetes None 
Symptoms of COVID-19  Dry cough, fever, 
odynophagia, arthralgia, 
diarrhoea  
Dry cough, shivering, 
odynophagia, breathing 
difficulties, chest pain  
Productive cough, fever, 
myalgia, vasovagal syncope, 
diarrhoea, nausea and 
vomiting 
Method for COVID-19 
diagnosis 
Antibodies for SARS-CoV-2 
IgM/IgG, followed by RT-PCR 
positive in nasopharyngeal 
swab (4th test) 
RT-PCR in nasopharyngeal 
swab (2nd test) 
RT-PCR in nasopharyngeal 
swab 
Neurological signs and 
symptoms 
Back pain, limb weakness, 
ataxia, distal paresthesia, 
dysgeusia, cacosmia.  
Developed respiratory failure, 
dysautonomia and tetraplegia 
with areflexia (day 4) 
Lower limb pain, mild 
weakness and normal deep 
tendon reflexes. Developed 
tetraparesis, distal 
paresthesia and areflexia 
(day 5) 
Lower limb weakness and 
distal paresthesia, dizziness, 
dysphagia, dysautonomia, 
areflexia. Presented 
worsening of bulbar 
symptoms and bilateral facial 
palsy (day 4) 
Time of neurological symptom 
onset (days) 
15 7 22 
Cerebrospinal fluid findings White cell count 3 cell/µL; 
Protein level 60 mg/dl; 
Negative PCR assay for 
SARS-CoV-2 (day 2) 
White cell count 2 cell/µL; 
Protein level 40 mg/dl; PCR 
assay for SARS-CoV-2 was 
not performed (day 6) 
White cell count 4 cell/µL; 
Protein level 140 mg/dl; 
Negative PCR assay for 
SARS-CoV-2 (day 1) 
Serum studies WBC 8900 cells/mm3; 
Lymphocytes 1200 cells/mm3; 
Platelets 45500 cells/mm3. 
Normal kidney and liver 
function. Antibodies to 
WBC 3300 cells/mm3; 
Lymphocytes 800 cells/mm3; 
Platelets 119000 cells/mm3. 
Normal kidney function. 
Elevated transaminase levels 
WBC 4000 cells/mm3; 
Lymphocytes 600 cells/mm3; 
Platelets 322000 cells/mm3. 
Normal kidney and liver 










ganglioside panel* was 
negative 
(AST 65 U/l; N<45 U/l). 
Antibodies to ganglioside 
panel* was not performed 
mmol/l). Antibodies to 
ganglioside panel* was not 
performed 
MRI results Spinal cord: no nerve root 
gadolinium enhancement 
Not performed Spinal cord: lumbosacral 
nerve root enhancement. 
Normal brain imaging 
Treatment 1 cycle of IVIg (day 2) 1 cycle of IVIg (day 10) 1 cycle of IVIg (day 2) 
Clinical outcome at 5 weeks Improvement of tetraparesis. 
Able to stand up with 
assistance. GBS disability 
clinical score 4/6 
Dismissal with full motor 
recovery. Persistence of lower 
limb areflexia and distal 
paresthesia. GBS disability 
clinical score 1/6 
Improvement of tetraparesis 
and ability to walk with 
assistance. Persistence of 
neuropathic pain and distal 
paresthesia. GBS disability 
clinical score 3/6 
 
 
COVID-19 = coronavirus disease 2019; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; RT-PCR = reverse transcription 
polymerase chain reaction; WBC = white blood cell count; MRI = magnetic resonance imaging; IVIg = intravenous immunoglobulins 
*Anti-ganglioside antibodies panel includes anti-GM1, GD1a and GQ1b 
 
